Dae Gon Ha
Stock Analyst at Stifel
(2.32)
# 1,291
Out of 4,874 analysts
49
Total ratings
32.5%
Success rate
4.23%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABEO Abeona Therapeutics | Maintains: Buy | $21 → $20 | $5.90 | +238.98% | 2 | May 16, 2025 | |
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $2.12 | +41.51% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $84.02 | -11.93% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $7.38 | -59.35% | 4 | Sep 12, 2024 | |
| INZY Inozyme Pharma | Initiates: Buy | $16 | $4.00 | +300.00% | 1 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $9.61 | +565.97% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $142.69 | +54.18% | 4 | Sep 11, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $48 → $66 | $50.52 | +30.64% | 3 | Jun 20, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $37.13 | +242.04% | 2 | May 31, 2024 | |
| VERV Verve Therapeutics | Maintains: Buy | $56 → $40 | $11.26 | +255.40% | 3 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $2.59 | +1,753.28% | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $2.65 | +579.25% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $0.34 | +1,955.80% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $61.58 | -59.40% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $5.69 | +181.20% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $8.28 | +3,342.03% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $2.16 | +825.93% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.02 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $18.40 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $9.66 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.83 | +1,341.27% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $9.21 | +5,220.30% | 2 | Oct 23, 2017 |
Abeona Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $21 → $20
Current: $5.90
Upside: +238.98%
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $2.12
Upside: +41.51%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $84.02
Upside: -11.93%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $7.38
Upside: -59.35%
Inozyme Pharma
Sep 12, 2024
Initiates: Buy
Price Target: $16
Current: $4.00
Upside: +300.00%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $9.61
Upside: +565.97%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $142.69
Upside: +54.18%
Mirum Pharmaceuticals
Jun 20, 2024
Maintains: Buy
Price Target: $48 → $66
Current: $50.52
Upside: +30.64%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $37.13
Upside: +242.04%
Verve Therapeutics
Apr 3, 2024
Maintains: Buy
Price Target: $56 → $40
Current: $11.26
Upside: +255.40%
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $2.59
Upside: +1,753.28%
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $2.65
Upside: +579.25%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $0.34
Upside: +1,955.80%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $61.58
Upside: -59.40%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $5.69
Upside: +181.20%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $8.28
Upside: +3,342.03%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $2.16
Upside: +825.93%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.02
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $18.40
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $9.66
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $0.83
Upside: +1,341.27%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $9.21
Upside: +5,220.30%